A week in the life of a researcher
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
Search
Search results
jCyte have released additional preclinical data regarding jCell
jCyte have released additional preclinical data regarding jCell
Webinar: Supporting Retina UK and what it can do for you
Our speakers tell us about the many positive impacts fundraising has had for them, including for their emotional wellbeing, and the many surprises along the way.
Podcast: Introducing our new chair
A new Retina UK podcast that introduces our new chair of trustees, Kathy Evans.
Meet our community: James Clarke
Aged 20, James was diagnosed with retinitis pigmentosa at a routine eye appointment in September 2015 and registered partially sighted, just prior to buying his first car and taking his driving test.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Peak District Challenge
Walk, jog or run 25, 50 or 100km from the Bakewell Base Camp and take in Derbyshire’s finest scenery.
Webinar: Getting active: sport and sight loss with British Blind Sport
Join us for our upcoming webinar!
Leaflet: Are you supporting someone with inherited sight loss
A guide for professionals. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future. We also support professionals working with them.
ProQR announces suspension of LCA10 and USH2A clinical trials
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.